Severe Dengue: all 65 studies

Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• Gut Leakage' in DengueRecruitingNCT07602920
• Therapeutics for Moderate and Severe DengueNot yet recruitingNCT07543458Phase 3
• Innovative Multidisciplinary Strategies for Combating Severe DengueRecruitingNCT06751836
• Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)RecruitingNCT05631405Not applicable
• NT-proBNP and Troponin I in Dengue ChildrenRecruitingNCT04837430
• Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®CompletedNCT02993757Phase 3Results posted
• Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy SubjectsTerminatedNCT02992418Phase 3Results posted
• Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®CompletedNCT02979535Phase 3Results posted
• Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose ScheduleCompletedNCT02824198Phase 2Results posted
• Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive AdultsCompletedNCT02741128Phase 2Results posted
• Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of AgeCompletedNCT02628444Phase 2Results posted
• Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose ScheduleCompletedNCT02623725Phase 2Results posted
• Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy StudyCompletedNCT01983553Results posted
• Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue VaccineCompletedNCT01943825Phase 2Results posted
• A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy AdultsCompletedNCT01666652Phase 1Results posted
• Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in IndiaCompletedNCT01550289Phase 2Results posted
• Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever VaccineCompletedNCT01488890Phase 2Results posted
• Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy ToddlersCompletedNCT01436396Phase 3Results posted
• Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy ToddlersCompletedNCT01411241Phase 3Results posted
• Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin AmericaCompletedNCT01374516Phase 3Results posted
• Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in AsiaCompletedNCT01373281Phase 3Results posted
• Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in MalaysiaCompletedNCT01254422Phase 3Results posted
• Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South AmericaCompletedNCT01187433Phase 2Results posted
• Study of a Tetravalent Dengue Vaccine in Healthy Adults in AustraliaCompletedNCT01134263Phase 3Results posted
• Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin AmericaCompletedNCT00993447Phase 2Results posted
• Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in SingaporeCompletedNCT00880893Phase 2Results posted
• Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy SubjectsCompletedNCT00875524Phase 2Results posted
• Efficacy and Safety of Dengue Vaccine in Healthy ChildrenCompletedNCT00842530Phase 2Results posted
• Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 YearsCompletedNCT00788151Phase 2Results posted
• Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the USCompletedNCT00617344Phase 2Results posted
• A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and ChildrenCompletedNCT00468858Phase 2Results posted
• Evaluating Public Awareness and Preventive Actions for Dengue Fever in Sudan Amidst Ongoing CrisesCompletedNCT07205848
• The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue FeverCompletedNCT06744777Phase 3
• Clinical and Laboratory Factors for the Progression of Severe Dengue Among Hospitalized Patients During an UpsurgeCompletedNCT06697041
• Efficacy of Fresh Frozen Plasma (FFP) in Treating Thrombocytopenia in Dengue PatientsActive, not recruitingNCT06642493Not applicable
• Severe Dengue in Critical Care at Villavicencio, Colombia.CompletedNCT05938647
• Anakinra in Dengue With Hyperinflammation ( AnaDen )Active, not recruitingNCT05611710Phase 2
• Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue PatientsCompletedNCT04673422Phase 2/3
• Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in SingaporeCompletedNCT04048837
• Dengue Effectiveness Study in the PhilippinesCompletedNCT03803618
• Dengue Serostatus Study in the PhilippinesActive, not recruitingNCT03465254
• Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue PatientsCompletedNCT03432442Phase 2
• Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue VaccineCompletedNCT02948933
• Ketotifen as a Treatment for Vascular Leakage During Dengue FeverStatus unknownNCT02673840Phase 4
• A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)CompletedNCT01702857Phase 1
• Prospective Dengue Seroprevalence Study in 5 to 10 Year-old ChildrenCompletedNCT01477671
• Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus VaccineCompletedNCT01436422Phase 1
• Cohort of Patients Infected by an ArbovirusStatus unknownNCT01099852
• Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 VaccineCompletedNCT01084291Phase 1
• Safety and Immune Response to an Investigational Dengue Type 2 VaccineCompletedNCT01073306Phase 1
• Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus VaccineCompletedNCT01072786Phase 1
• A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the PhilippinesCompletedNCT01064141Phase 2
• Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS)Status unknownNCT00966628Phase 3
• Study of HBV-001 D1 in Healthy AdultsCompletedNCT00936429Phase 1
• Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue VirusCompletedNCT00919178Phase 1
• Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy AdultsCompletedNCT00831012Phase 1
• Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve AdultsCompletedNCT00740155Phase 2
• Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult SubjectsCompletedNCT00730288Phase 2
• Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus VaccineCompletedNCT00473135Phase 1
• Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue VirusCompletedNCT00458120Phase 1
• Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy AdultsCompletedNCT00375726Phase 1
• Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy AdultsCompletedNCT00322946Phase 1
• Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy AdultsCompletedNCT00270699Phase 1
• Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy AdultsCompletedNCT00094705Phase 1
• Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy AdultsCompletedNCT00089908Phase 1

← Severe Dengue overview